Market Size & Trends

The European peripheral vascular angiography contrast media market is witnessing substantial growth, driven by the rising demand for advanced diagnostic solutions amid the increasing prevalence of age-related health issues. The market size in 2024 is estimated at USD 207.33 million, with an expected compound annual growth rate (CAGR) of 5.63% from 2025 to 2030. This growth is primarily fueled by the rising incidence of peripheral vascular diseases, diabetes, and cardiovascular conditions among the aging population. Notably, 74 million adults in Europe are currently living with diabetes, representing approximately 11.9% of men and 10.9% of women. Projections indicate that by 2045, nearly one in ten Europeans will be affected, as both aging and rising risk factors, such as obesity, continue to drive this trend.

GET FREE SAMPLE PAGES-https://www.theresearchinsights.com/reports/europe-peripheral-vascular-angiography-contrast-media-market-785/request-sample

The growing burden of cardiovascular diseases (CVDs) is also propelling the demand for peripheral vascular angiography contrast media. Conditions such as peripheral artery disease (PAD) and atherosclerosis require precise imaging to facilitate early diagnosis and effective treatment planning. The increasing number of CVD patients is leading to a higher demand for angiography procedures, further boosting the growth of the contrast media market.

As vascular imaging procedures become more critical, the demand for high-quality image clarity is intensifying. This is crucial for accurate diagnoses and guiding interventions. Cardiovascular diseases are the leading cause of death and disability in Europe, with an estimated 10,000 deaths every day, according to the World Health Organization (WHO), emphasizing the need for enhanced diagnostic imaging.

The aging demographic in Europe plays a significant role in this market's expansion, as older individuals are more susceptible to vascular diseases like PAD, atherosclerosis, and deep vein thrombosis (DVT). With over 21.3% of the EU population aged 65 and above as of 2023, there is a growing need for advanced diagnostic imaging solutions.

Key players in the European peripheral vascular angiography contrast media market include Bayer AG (Germany), Bracco (Italy), and Guerbet (France). Guerbet, for example, has reported strong performance, particularly within its MRI segment, positioning itself for continued growth in contrast media sales in 2024.

Market Dynamics & Characteristics

The European market for peripheral vascular angiography contrast media is at a medium-to-high growth stage, driven by technological innovations and advancements in imaging technologies. Recent developments include nanoparticle-based contrast media, dual-energy CT-compatible agents, and low-dose solutions designed to reduce nephrotoxicity risks. Companies are also integrating AI-driven contrast injection systems, which optimize contrast use while reducing patient exposure, ensuring accurate imaging.

In parallel, the regulatory landscape continues to evolve, with agencies like the European Medicines Agency (EMA) setting rigorous standards for contrast media manufacturing and clinical use. Regulations such as restrictions on gadolinium-based contrast agents have led to a rise in the use of iodinated and microbubble alternatives, with growing attention to eco-friendly and biodegradable solutions.

Strategic partnerships between contrast media manufacturers and healthcare providers are becoming more common, as both entities recognize the importance of integrating advanced products and optimizing supply chains. These collaborations aim to accelerate innovation and enhance patient access to high-quality contrast media solutions.

Modality Insights

The demand for CT and X-ray imaging technologies remains robust, with CT angiography leading the charge due to its ability to provide detailed, high-quality images of vascular structures. The role of iodinated contrast agents in CT angiography is crucial, as they offer excellent image enhancement and rapid distribution, making them ideal for identifying vascular abnormalities such as arterial blockages and aneurysms.

Ultrasound technology is expected to experience rapid growth in the coming years, with an increasing adoption of contrast-enhanced ultrasound for peripheral vascular imaging. This non-invasive method offers a cost-effective alternative to CT and MRI angiography while providing real-time diagnostic capabilities. The use of ultrasound-specific contrast media has significantly enhanced the diagnostic clarity of blood flow and vascular structures, driving demand for these solutions in the clinical setting.

Product Insights

Iodinated contrast media remain the market leader, accounting for a substantial share of revenue in 2024. These agents are widely used in CT and X-ray angiography procedures due to their ability to provide superior imaging clarity and rapid vascular enhancement. The demand for iodinated contrast media continues to rise, driven by the increasing incidence of cardiovascular and peripheral vascular diseases.

The microbubble contrast media segment is set for significant growth, particularly in ultrasound imaging applications. These agents offer enhanced visibility of vascular structures, providing real-time imaging that supports more accurate diagnostics. With the rising preference for non-invasive diagnostic procedures, microbubble contrast agents are becoming an essential tool in modern medical imaging.

End Use Insights

The European peripheral vascular angiography contrast media market in 2024 was largely driven by hospital end-users, who leveraged advanced imaging infrastructure and cutting-edge diagnostic technologies to perform an increasingly large volume of angiographic procedures. Hospitals play a critical role in diagnosing and managing conditions such as PAD, DVT, and atherosclerosis, which necessitates the use of high-quality contrast media for enhanced imaging capabilities.

In addition to their cutting-edge technology, hospitals also boast well-equipped radiology and catheterization labs that enable advanced digital subtraction angiography (DSA), CT angiography (CTA), and MR angiography (MRA) techniques - all of which rely on contrast media for crystal-clear vascular visualization. The presence of highly skilled medical professionals, including interventional radiologists and vascular surgeons, further solidifies a hospital's position in the market, as these specialists require high-quality contrast-enhanced imaging for accurate diagnosis and treatment planning.

 

The European peripheral vascular angiography contrast media market is expected to witness substantial growth from 2025 to 2030, driven primarily by the increasing need for advanced diagnostic imaging solutions. The growing prevalence of age-related diseases such as diabetes and cardiovascular conditions is contributing to an rise in peripheral vascular disease cases, fueling demand for more sophisticated diagnostic tools.

The integration of cutting-edge technologies in angiographic imaging is revolutionizing the way contrast media is utilized within imaging centers. The rapid adoption of digital subtraction angiography (DSA) alongside high-resolution CT and MRI angiography is driving demand for these contrast agents, making them more readily available across a broader network of freestanding diagnostic facilities. Moreover, the growing preference for outpatient imaging services is expanding access to peripheral vascular angiography, thereby alleviating pressure on hospital resources. Furthermore, supportive reimbursement policies, increased healthcare investments, and ongoing enhancements in diagnostic infrastructure across Europe are all contributing factors to market growth.

Key Europe Peripheral Vascular Angiography Contrast Media Company Insights

As companies navigate the ever-evolving landscape, they're shifting their focus towards introducing innovative products and enriching their offerings through strategic expansions. Meanwhile, industry leaders are also prioritizing acquisitions as a key means of bolstering their competitiveness within this fast-paced market.

Key Europe Peripheral Vascular Angiography Contrast Media Companies:

• Guerbet
• Bracco
• Bayer
• GE HealthCare
• Fresenius Kabi USA
• Lantheus Holdings, Inc.

Recent Developments

• In July 2024, Bracco and Verasonics, Inc. strategically partnered together to enhance research in medical imaging. This collaboration will merge Verasonics' Vantage NXT Research Ultrasound Systems with Bracco's contrast agents to investigate enhanced imaging performance across various research applications. The agreement also entails joint marketing initiatives, including online content and webinars, to present the outcomes of their research efforts.

• In May 2024, Guerbet established a strategic partnership with NUCLIDIUM to drive the development of copper-based radiotheranostics, aiming to enhance precision diagnostics and targeted therapy in nuclear medicine.

• In April 2024, The Bracco Group announced it will launch its direct autonomous presence in the Japanese market starting April 2024. Bracco Japan will gradually replace Bracco Eisai, the joint venture established in 1990 and renewed twice.

• Get in Touch with Us

  US +1 312-313-8080
  India +91-89564-46619

   [email protected]

• Company Address

   1331 Johnson Dr, Buffalo, Grove. illinios, Chicago, USA.